NCT00709683View on ClinicalTrials.gov

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

CompletedOBSERVATIONAL

Enrollment

216

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Trial Locations (1)

1053

Tunisia

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT00709683 - Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen® | Biotech Hunter | Biotech Hunter